Approach to management of thrombotic thrombocytopenic Purpura at University of Cincinnati

Keyphrases

• Thrombotic Thrombocytopenic Purpura 100%
• Cincinnati 100%
• Approaches to Management 100%
• Plasma Exchange 50%
• Immunosuppressive Therapy 33%
• Rituximab 33%
• Etiology 16%
• Retrospective Analysis 16%
• Monoclonal Antibody 16%
• Renal Failure 16%
• B Lymphocytes 16%
• Thrombocytopenia 16%
• Relapse Rate 16%
• Ischemic Damage 16%
• Platelet Aggregation 16%
• Remission 16%
• Renal Abnormalities 16%
• Neurological Abnormalities 16%
• CD20 16%
• Steroid Therapy 16%
• Antibody-mediated Disease 16%
• Microangiopathic Hemolytic Anemia 16%
• Haematological Emergencies 16%

Medicine and Dentistry

• Thrombotic Thrombocytopenic Purpura 100%
• Plasma Exchange 42%
• Immunosuppressive Treatment 28%
• Rituximab 28%
• Disease 14%
• Renal Failure 14%
• Monoclonal Antibody 14%
• B Lymphocyte 14%
• Thrombocytopenia 14%
• Recurrence Risk 14%
• Thrombocyte Aggregation 14%
• CD20 14%
• Steroid Therapy 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Thrombotic Thrombocytopenic Purpura 100%
• Immunosuppressive Agent 28%
• Rituximab 28%
• Disease 14%
• Monoclonal Antibody 14%
• Kidney Failure 14%
• Thrombocytopenia 14%
• Remission 14%
• Recurrence Risk 14%